Dapagliflozin for the Treatment of Type 2 Diabetes Mellitus

Abstract

As the second SGLT-2 inhibitor approved in the United States, dapagliflozin is safe and effective for treatment of type 2 diabetes mellitus. It appears to have no increased cardiovascular risk and provides a moderate benefit for patients with high blood pressure or those who are overweight. However, dapagliflozin was found to be associated with nasopharyngitis, mycotic infections, and genital or urinary tract infections. This medication may be best used as adjunctive therapy for patients not well-controlled on other antidiabetic agents. However, caution should be taken when used in patients at risk of urinary tract infections and dehydration.

Effect of Sodium‐Glucose Cotransport‐2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis of 43 Randomized Control Trials With 22 528 Patients

“…71 SGLT2 inhibitors, in addition to being effective in the treatment of T2D, appear to have benefits beyond glucose lowering, including effects on weight loss and raising highdensity lipoprotein cholesterol levels. 70,72 Therefore, SGLT2 inhibitors may play a significant role in reducing cardiovascular risk factors in people with T2D.…”

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review

“…In addition to microvascular complications (nephropathy, retinopathy and neuropathy), T2DM is associated with macrovascular complications including CVD, cerebrovascular disease and peripheral artery disease. Secondly, the majority of patients with T2DM are overweight or obese, a further risk factor for both CVD and hypertension [5]. …”

Quais os benefícios para o doente da associação de metformina com dapagliflozina comparativamente a outros antidiabéticos orais? Uma revisão baseada na evidência

“…Esta análise não foi realizada para as glitazonas por falta de dados. Na revisão sistemática de Aysworth e colaboradores 14 constatou-se uma redução do peso nos doentes tratados com dapagliflozina (-3,22kg), contrariamente a um aumento registado no grupo tratado com glipizida (1,44kg). Adicionalmente, quando comparado com placebo, a dapagliflozina associou-se a uma redução do peso e o placebo a um aumento.…”

“…Na revisão sistemática de Aylsworth e colaboradores 14 verificou-se que o risco relativo de hipoglicemia com a dapagliflozina é relativamente baixo.…”

“…A revisão sistemática de Aylsworth e colaboradores 14 identificou como efeitos secundários mais comuns as nasofaringites, as infeções do trato genital (ITG) e as infeções do trato urinário (ITU).…”